How to Help Your Patients Save Money on Mydayis XR: A Provider's Guide to Savings Programs

Mydayis XR provides clinically meaningful benefits for patients who need extended ADHD symptom coverage — but its cost can be a significant barrier to adherence. Without intervention, patients may face $345–$466 per month for brand-name Mydayis at retail. Even with insurance, high copays, step therapy requirements, and prior authorization hurdles can interrupt treatment.

This guide outlines actionable strategies providers can use — and share with patients — to reduce the out-of-pocket cost of Mydayis XR in 2026.

Understanding the Cost Landscape in 2026

Before discussing savings strategies, it helps to understand what patients are actually paying:

• Brand Mydayis (retail, no insurance): $345–$466 per month (30-day supply, varies by strength and pharmacy)
• Generic Mydayis (retail, no discount): $200–$350 per month — availability inconsistent due to ongoing shortage
• Generic Mydayis with GoodRx coupon: as low as $92–$150 per month — a 74% or greater savings off retail
• With insurance: Copays vary widely. Mydayis may be on Tier 3 or specialty tier, requiring prior authorization or step therapy.

The key insight: the difference between what a patient pays at full retail versus what they pay with a coupon card on the generic can be $300+ per month. This is information worth sharing proactively at every Mydayis prescription.

Strategy 1: Always Prescribe Generic First

The FDA-approved generic version of Mydayis (mixed amphetamine salts extended-release, triple-bead formulation) is therapeutically equivalent to brand Mydayis. Prescribing generic by default — unless there is a specific clinical reason for brand — is the single most impactful step toward cost reduction.

Note: Generic Mydayis availability remains inconsistent due to the ongoing amphetamine shortage. Advise patients to check stock at multiple pharmacies or use a pharmacy locator tool before assuming the generic is available.

Strategy 2: Recommend Prescription Discount Cards

Prescription discount cards like GoodRx, SingleCare, RxSaver, and Optum Perks can dramatically reduce the out-of-pocket cost for uninsured patients — and sometimes for insured patients whose copay exceeds the coupon price. Key points to communicate to patients:

• GoodRx and SingleCare are free to use — patients simply show the card or app to the pharmacist
• Generic Mydayis with GoodRx can cost as little as $92/month — compare this to brand-name retail at $345–$466
• Prices vary by pharmacy, so it's worth comparing across pharmacies in the patient's area
• Discount cards cannot be combined with insurance — patients should compare the coupon price to their insurance copay

Strategy 3: Navigate Insurance Formularies Proactively

Mydayis is commonly placed on Tier 3 or specialty tiers with higher copays, and many plans require prior authorization or step therapy. Providers who proactively manage these requirements save patients significant cost and frustration.

Prior authorization: Submit a PA at the time of prescribing rather than waiting for a pharmacy rejection. Key clinical justifications to include:

• The patient's specific need for extended coverage (16+ hours) that Adderall XR or Vyvanse cannot provide
• Documentation of prior trials with shorter-acting alternatives and why they were inadequate
• Clinical evidence that symptoms persist into evening hours and affect work, school, or family obligations

Step therapy appeals: If a plan requires the patient to fail on Adderall XR first, document any prior trial or provide clinical reasoning for why Mydayis's 16-hour duration is specifically medically necessary for this patient.

Mail-order pharmacy: Many insurance plans offer reduced copays for 90-day supplies via mail-order. This also reduces the frequency with which patients need to manage prescription renewals.

Strategy 4: Patient Assistance Programs

For uninsured or underinsured patients facing financial hardship, several assistance programs may help:

• Patient Access Network (PAN) Foundation — Assists patients with income below 400% of the federal poverty level who have Medicare. Eligibility and availability by indication — check panfoundation.org for current programs.
• HealthWell Foundation — Provides copay assistance for insured patients struggling with out-of-pocket costs. Check healthwellfoundation.org for open funds.
• Patient Advocate Foundation Co-Pay Relief — Direct payment for copays, coinsurance, and deductibles for qualifying insured patients.
• NeedyMeds (needymeds.org) — A free database of assistance programs. Useful for finding state-level programs that may apply to your patient's situation.

Note: As of 2025–2026, Takeda's Help at Hand Patient Assistance Program has discontinued Mydayis as a covered medication. Providers and patients should not rely on this program and should explore the alternatives listed above.

Strategy 5: Consider Cost When Deciding Between Strengths

Prescribers may not realize that different dose strengths can have significantly different prices — sometimes two lower-dose capsules cost less than one higher-dose capsule, or vice versa. Advise cost-sensitive patients to:

• Use GoodRx or a similar tool to compare prices across all available strengths at local pharmacies
• Ask the pharmacist to run both the insurance price and the coupon price — use whichever is lower
• Check whether prescribing two 12.5 mg capsules daily is more cost-effective than one 25 mg capsule (or any other strength combination that achieves the target dose)

Helping Patients Find Mydayis in Stock

Cost is only one barrier — availability is the other. Due to the ongoing amphetamine shortage, Mydayis remains intermittently out of stock at many pharmacies. Medfinder for Providers is a real-time pharmacy availability tool you can share with patients or check during appointments to identify which pharmacies near them have Mydayis in stock. For more on this topic, see our provider guide: How to Help Your Patients Find Mydayis XR in Stock.

When Cost Makes Mydayis Untenable: Clinical Alternatives

If, after exhausting savings programs, Mydayis remains unaffordable for a patient, consider the following alternatives that may provide similar therapeutic benefit at lower cost:

• Generic Adderall XR — $30–$80 with a coupon; 10–12 hours of coverage; most commonly prescribed alternative
• Generic Vyvanse (lisdexamfetamine) — $30–$80 with a coupon; 12–14 hours of coverage; prodrug mechanism reduces misuse potential
• Generic Concerta (methylphenidate ER) — $25–$60 with a coupon; different mechanism class; good option when amphetamines are unavailable or not tolerated

Addressing medication cost proactively is one of the most impactful things a prescriber can do to improve adherence. Patients who can't afford their medication don't fill it — and undertreated ADHD carries its own significant costs to quality of life, productivity, and safety. For more resources designed specifically for providers managing ADHD medications during the shortage, visit Medfinder for Providers.